Autor: |
Lu Zhang, Lingeng Wu, Qiuying Chen, Bin Zhang, Jing Liu, Shuyi Liu, Xiaokai Mo, Minmin Li, Zhuozhi Chen, Luyan Chen, Jingjing You, Zhe Jin, Xudong Chen, Zejian Zhou, Shuixing Zhang |
Jazyk: |
angličtina |
Rok vydání: |
2021 |
Předmět: |
|
Zdroj: |
EClinicalMedicine, Vol 31, Iss , Pp 100673- (2021) |
Druh dokumentu: |
article |
ISSN: |
2589-5370 |
DOI: |
10.1016/j.eclinm.2020.100673 |
Popis: |
Background: Hyperprogressive disease (HPD) is a new progressive pattern in patients with advanced hepatocellular carcinoma (HCC) treated with programmed cell death 1 (PD-1) inhibitors. We aimed to investigate risk factors associated with HPD in advanced HCC patients undergoing anti-PD-1 therapy. Methods: A total of 69 patients treated with anti-PD-1 therapy between March 2017 and January 2020 were included. HPD was determined according to the time to treatment failure, tumour growth rate, and tumour growth rate ratio. Univariate and multivariate analyses were performed to identify clinical variables significantly associated with HPD. A risk model was constructed based on clinical variables with prognostic significance for HPD. Findings: Overall, 10 (14·49%) had HPD. Haemoglobin level, portal vein tumour thrombus, and Child-Pugh score were significantly associated with HPD. The risk model had an area under the curve of 0·931 (95% confidence interval, 0·844–1·000). Patients with HPD had a significantly shorter overall survival (OS) than that of the patients with non-HPD (p |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|